190 related articles for article (PubMed ID: 31650173)
1. LncRNA-MALAT1 mediates cisplatin resistance via miR-101-3p/VEGF-C pathway in bladder cancer.
Liu P; Li X; Cui Y; Chen J; Li C; Li Q; Li H; Zhang X; Zu X
Acta Biochim Biophys Sin (Shanghai); 2019 Nov; 51(11):1148-1157. PubMed ID: 31650173
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of long non-coding RNA metastasis associated lung adenocarcinoma transcript 1 inhibits the proliferation and migration of bladder cancer cells by modulating the microRNA-34a/cyclin D1 axis.
Liu Y; Gao S; Du Q; Zhao Q
Int J Mol Med; 2019 Jan; 43(1):547-556. PubMed ID: 30387807
[TBL] [Abstract][Full Text] [Related]
3. LncRNA MALAT1 promotes breast cancer progression and doxorubicin resistance via regulating miR-570-3p.
Yue X; Wu WY; Dong M; Guo M
Biomed J; 2021 Dec; 44(6 Suppl 2):S296-S304. PubMed ID: 35410813
[TBL] [Abstract][Full Text] [Related]
4. LncRNA MST1P2/miR-133b axis affects the chemoresistance of bladder cancer to cisplatin-based therapy via Sirt1/p53 signaling.
Chen J; Li Y; Li Z; Cao L
J Biochem Mol Toxicol; 2020 Apr; 34(4):e22452. PubMed ID: 32052927
[TBL] [Abstract][Full Text] [Related]
5. LncRNA HOXA11-AS Promotes Proliferation and Cisplatin Resistance of Oral Squamous Cell Carcinoma by Suppression of miR-214-3p Expression.
Wang X; Li H; Shi J
Biomed Res Int; 2019; 2019():8645153. PubMed ID: 31275988
[TBL] [Abstract][Full Text] [Related]
6. LncRNA MALAT1 potentiates autophagy‑associated cisplatin resistance by regulating the microRNA‑30b/autophagy‑related gene 5 axis in gastric cancer.
Xi Z; Si J; Nan J
Int J Oncol; 2019 Jan; 54(1):239-248. PubMed ID: 30365113
[TBL] [Abstract][Full Text] [Related]
7. Exosomal LINC00355 derived from cancer-associated fibroblasts promotes bladder cancer cell resistance to cisplatin by regulating miR-34b-5p/ABCB1 axis.
Luo G; Zhang Y; Wu Z; Zhang L; Liang C; Chen X
Acta Biochim Biophys Sin (Shanghai); 2021 Apr; 53(5):558-566. PubMed ID: 33720323
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of MALAT1 enhances chemosensitivity of ovarian cancer cells to cisplatin through inhibiting the Notch1 signaling pathway.
Bai L; Wang A; Zhang Y; Xu X; Zhang X
Exp Cell Res; 2018 May; 366(2):161-171. PubMed ID: 29548748
[TBL] [Abstract][Full Text] [Related]
9. MALAT1/miR-101-3p/MCL1 axis mediates cisplatin resistance in lung cancer.
Wang H; Wang L; Zhang G; Lu C; Chu H; Yang R; Zhao G
Oncotarget; 2018 Jan; 9(7):7501-7512. PubMed ID: 29484127
[TBL] [Abstract][Full Text] [Related]
10. miR-101 suppresses vascular endothelial growth factor C that inhibits migration and invasion and enhances cisplatin chemosensitivity of bladder cancer cells.
Lei Y; Li B; Tong S; Qi L; Hu X; Cui Y; Li Z; He W; Zu X; Wang Z; Chen M
PLoS One; 2015; 10(2):e0117809. PubMed ID: 25658842
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-203 Is a Prognostic Indicator in Bladder Cancer and Enhances Chemosensitivity to Cisplatin via Apoptosis by Targeting Bcl-w and Survivin.
Zhang X; Zhang Y; Liu X; Fang A; Li P; Li Z; Liu T; Yang Y; Du L; Wang C
PLoS One; 2015; 10(11):e0143441. PubMed ID: 26599571
[TBL] [Abstract][Full Text] [Related]
12. Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer.
YiRen H; YingCong Y; Sunwu Y; Keqin L; Xiaochun T; Senrui C; Ende C; XiZhou L; Yanfan C
Mol Cancer; 2017 Nov; 16(1):174. PubMed ID: 29162158
[TBL] [Abstract][Full Text] [Related]
13. Metformin, a first-line drug for type 2 diabetes mellitus, disrupts the MALAT1/miR-142-3p sponge to decrease invasion and migration in cervical cancer cells.
Xia C; Liang S; He Z; Zhu X; Chen R; Chen J
Eur J Pharmacol; 2018 Jul; 830():59-67. PubMed ID: 29704494
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 regulates the expression of Gli2 by miR-202 to strengthen gastric cancer progression.
Zhang Y; Chen Z; Li MJ; Guo HY; Jing NC
Biomed Pharmacother; 2017 Jan; 85():264-271. PubMed ID: 27887846
[TBL] [Abstract][Full Text] [Related]
15. MiR-193b Mediates CEBPD-Induced Cisplatin Sensitization Through Targeting ETS1 and Cyclin D1 in Human Urothelial Carcinoma Cells.
Lin SR; Yeh HC; Wang WJ; Ke HL; Lin HH; Hsu WC; Chao SY; Hour TC; Wu WJ; Pu YS; Huang AM
J Cell Biochem; 2017 Jun; 118(6):1563-1573. PubMed ID: 27918099
[TBL] [Abstract][Full Text] [Related]
16. The lncRNA MALAT1 functions as a competing endogenous RNA to regulate MCL-1 expression by sponging miR-363-3p in gallbladder cancer.
Wang SH; Zhang WJ; Wu XC; Weng MZ; Zhang MD; Cai Q; Zhou D; Wang JD; Quan ZW
J Cell Mol Med; 2016 Dec; 20(12):2299-2308. PubMed ID: 27420766
[TBL] [Abstract][Full Text] [Related]
17. Repression of GRIM19 expression potentiates cisplatin chemoresistance in advanced bladder cancer cells via disrupting ubiquitination-mediated Bcl-xL degradation.
Ni F; Yan CY; Zhou S; Hui PY; Du YH; Zheng L; Yu J; Hu XJ; Zhang ZG
Cancer Chemother Pharmacol; 2018 Oct; 82(4):593-605. PubMed ID: 30032449
[TBL] [Abstract][Full Text] [Related]
18. VEGF-C inhibition reverses resistance of bladder cancer cells to cisplatin via upregulating maspin.
Zhu H; Yun F; Shi X; Wang D
Mol Med Rep; 2015 Aug; 12(2):3163-9. PubMed ID: 25936422
[TBL] [Abstract][Full Text] [Related]
19. LncRNA-MALAT1 contributes to the cisplatin-resistance of lung cancer by upregulating MRP1 and MDR1 via STAT3 activation.
Fang Z; Chen W; Yuan Z; Liu X; Jiang H
Biomed Pharmacother; 2018 May; 101():536-542. PubMed ID: 29505924
[TBL] [Abstract][Full Text] [Related]
20. LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis.
Wei S; Wang K; Huang X; Zhao Z; Zhao Z
Int J Immunopathol Pharmacol; 2019; 33():2058738419859699. PubMed ID: 31240979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
